L-arginine Cardiovascular Randomized Trial: What the Evidence Says

Quick Answer

L-arginine Cardiovascular Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• More importantly, this BP elevation was closely associated with adverse outcomes, with cardiovascular mortality risk increasing by 21% for every 10 mmHg increase in SBP, and winter cardiovascular mortality rates being 41% higher than those in summer (Yang et al. ). [Luo Ping (2026); evidence level 1]
• Given that cold environment-induced BP elevation is one of the important modifiable risk factors for CVD (Gu et al. ; Yokoyama et al. ), targeted interventions to control elevated BP during cold weather are particularly crucial (Xu et al. ,). [Luo Ping (2026); evidence level 1]
• This is based on evidence from numerous randomized studies showing that treating patients with these BP values leads to benefits in the prevention and management of systemic diseases. [Abate Federico (2026); evidence level 2]
• The continuous relationship between blood pressure and the risk of cardiovascular events has been demonstrated at all ages and across all ethnic groups and extends from high BP levels to relatively low values. [Abate Federico (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For l-arginine cardiovascular randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Luo Ping (2026). Effect of L‐Citrulline Intake on Blood Pressure in Cold Environments: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. DOI: 10.1002/fsn3.71603. PMCID: PMC12965904. PMID: 41797970. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12965904/
• Abate Federico (2026). A Nutraceutical Approach for Hypertension: Randomized Controlled Trial of Grape Pomace Extract and L-Arginine. DOI: 10.3390/antiox15030329. PMCID: PMC13023866. PMID: 41897475. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13023866/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.